Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
Nelson AJ, Kaltenbach LA, McGuire DK, Levya M, Al-Khalidi HR, Webb L, Lopes RD, Pop-Busui R, Cavender MA, Aroda VR, Magwire ML, Richardson CR, Lingvay I, Kirk JK, Pandey A, Gaynor T, Pak J, Washington A, Senyucel C, Green JB, Granger CB, Pagidipati NJ. Nelson AJ, et al. Among authors: pagidipati nj. Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.12.006. Online ahead of print. Am Heart J. 2024. PMID: 39716628
Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.
Nelson AJ, Ardissino M, Haynes K, Shambhu S, Eapen ZJ, McGuire DK, Carnicelli A, Lopes RD, Green JB, O'Brien EC, Pagidipati NJ, Granger CB. Nelson AJ, et al. Among authors: pagidipati nj. J Am Heart Assoc. 2021 Jan 19;10(2):e016835. doi: 10.1161/JAHA.120.016835. Epub 2021 Jan 12. J Am Heart Assoc. 2021. PMID: 33432843 Free PMC article.
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, Al-Khalidi H, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Reed M, Senyucel C, Webb L, McGuire DK, Granger CB. Nelson AJ, et al. Among authors: pagidipati nj. Circulation. 2021 Jul 6;144(1):74-84. doi: 10.1161/CIRCULATIONAHA.121.053766. Epub 2021 Jul 6. Circulation. 2021. PMID: 34228476 Review.
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Nelson AJ, O'Brien EC, Kaltenbach LA, Green JB, Lopes RD, Morse CG, Al-Khalidi HR, Aroda VR, Cavender MA, Gaynor T, Kirk JK, Lingvay I, Magwire ML, McGuire DK, Pak J, Pop-Busui R, Richardson CR, Senyucel C, Kelsey MD, Pagidipati NJ, Granger CB. Nelson AJ, et al. Among authors: pagidipati nj. JAMA Netw Open. 2022 Feb 1;5(2):e2148030. doi: 10.1001/jamanetworkopen.2021.48030. JAMA Netw Open. 2022. PMID: 35175345 Free PMC article.
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.
Nelson AJ, Pagidipati NJ, Kelsey MD, Ardissino M, Aroda VR, Cavender MA, Lopes RD, Al-Khalidi HR, Braceras R, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Levya M, Senyucel C, Webb L, McGuire DK, Green JB, Granger CB. Nelson AJ, et al. Among authors: pagidipati nj. Am Heart J. 2023 Feb;256:2-12. doi: 10.1016/j.ahj.2022.10.079. Epub 2022 Oct 21. Am Heart J. 2023. PMID: 36279931 Clinical Trial.
Risk of Total Events With Icosapent Ethyl: Can We Reduce It?
Granger CB, Nelson AJ, Pagidipati NJ. Granger CB, et al. Among authors: pagidipati nj. J Am Coll Cardiol. 2019 Jun 11;73(22):2803-2805. doi: 10.1016/j.jacc.2019.03.492. J Am Coll Cardiol. 2019. PMID: 31171085 Free article. No abstract available.
134 results